^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lucentis (ranibizumab)

    i
    Other names: RG-3645, RG 3645, rhuFabV2, RG3645
    Associations

    News

    Trials
    Company:
    China Medical System, Novartis, Roche, Santen
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    Associations

    News

    Trials
    5d
    PAVILION: A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (clinicaltrials.gov)
    P3, N=174, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    Lucentis (ranibizumab)
    11d
    Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P3, N=561, Recruiting, AbbVie
    Trial initiation date • Adverse events • Real-world evidence
    |
    Lucentis (ranibizumab)
    22d
    VOYAGER: A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (clinicaltrials.gov)
    P=N/A, N=6000, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Mar 2027 --> Nov 2026
    Trial primary completion date • Real-world evidence
    |
    Lucentis (ranibizumab)
    22d
    Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=510, Completed, Laboratorios Sophia S.A de C.V. | Recruiting --> Completed
    Trial completion • Head-to-Head
    |
    Avastin (bevacizumab) • Lucentis (ranibizumab)
    1m
    AAVIATE: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P2, N=146, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Lucentis (ranibizumab)
    2ms
    MR45625: Phase IIIb Study of 36-Week Refill Exchanges of Port Delivery System with Ranibizumab in nAMD (2024-516924-32-00)
    P2/3, N=164, Recruiting, F. Hoffmann-La Roche AG
    New P2/3 trial
    |
    Lucentis (ranibizumab)
    2ms
    A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD) (clinicaltrials.gov)
    P3, N=443, Completed, Jecho Biopharmaceuticals Co., Ltd.
    New P3 trial
    |
    Lucentis (ranibizumab)
    2ms
    Observation on the Efficacy of Ranibizumab Injection with 3+PRN Regimen Combined with PRP in the Treatment of DME (ChiCTR2500113346)
    P4, N=90, Not yet recruiting, Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
    New P4 trial
    |
    Lucentis (ranibizumab)
    2ms
    A single-arm, phase II clinical study of Sacituzumab Tirumotecan combined with Bevacizumab for the treatment of platinum-resistant epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer (ChiCTR2500112955)
    P2, N=30, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    Avastin (bevacizumab) • Jiataile (sacituzumab tirumotecan) • Lucentis (ranibizumab)
    3ms
    BURGUNDY: Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P1/2, N=177, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2028 --> Aug 2026 | Trial primary completion date: Feb 2027 --> Aug 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    Lucentis (ranibizumab)
    4ms
    VOYAGER: A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (clinicaltrials.gov)
    P=N/A, N=6000, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2026 --> Mar 2027
    Enrollment closed • Trial primary completion date • Real-world evidence
    |
    Lucentis (ranibizumab)
    4ms
    A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss (clinicaltrials.gov)
    P3, N=351, Completed, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Recruiting --> Completed
    Trial completion
    |
    Lucentis (ranibizumab)